Literature DB >> 10360378

WT1 and GATA1 expression in myelodysplastic syndrome and acute leukemia.

P Patmasiriwat1, G Fraizer, H Kantarjian, G F Saunders.   

Abstract

The Wilms' tumor protein, WT1, represses transcription from several growth factor genes. WT1 transcription is regulated in erythroid and myeloid lineages by the transcription factor GATA-1. Using a sensitive, isotopic duplex RT-PCR procedure amplifying WT1 or GATA-1 together with beta-actin as the internal control in a single reaction mix, we quantitated the expression of WT1 and GATA-1 mRNA of 16 patients with myelodysplastic syndrome (MDS), 56 with acute myeloid leukemia (AML) and 22 with acute lymphoblastic leukemia (ALL). K562 was used as reference positive control for this cell line expresses both WT1 and GATA-1. Among MDS patients, increased WT1 expression was found in refractory anemia with excess blast (RAEB) and RAEB in transformation (RAEB-T) subtypes compared to the normal controls, whereas WT1 expression in refractory anemia (RA) was not different from the normal control level. All of AML cases of subtypes M0, M1, M2 and M3 expressed WT1 more than three times the normal WT1 level. Subtypes M4 to M7 showed significantly lower WT1 levels than M1 to M3 and AML cases with CD14+ expressed less WT1 than CD14-. Higher than normal WT1 levels were also expressed in cases of ALL.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10360378     DOI: 10.1038/sj.leu.2401414

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  10 in total

Review 1.  The possible role and application of WT1 in human leukemia.

Authors:  Z Chen
Journal:  Int J Hematol       Date:  2001-01       Impact factor: 2.490

Review 2.  Active specific immunotherapy targeting the Wilms' tumor protein 1 (WT1) for patients with hematological malignancies and solid tumors: lessons from early clinical trials.

Authors:  Ann Van Driessche; Zwi N Berneman; Viggo F I Van Tendeloo
Journal:  Oncologist       Date:  2012-01-30

3.  Estrogen promotes megakaryocyte polyploidization via estrogen receptor beta-mediated transcription of GATA1.

Authors:  C Du; Y Xu; K Yang; S Chen; X Wang; S Wang; C Wang; M Shen; F Chen; M Chen; D Zeng; F Li; T Wang; F Wang; J Zhao; G Ai; T Cheng; Y Su; J Wang
Journal:  Leukemia       Date:  2016-10-17       Impact factor: 11.528

4.  NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: report from the Committee on Disease-Specific Methods and Strategies for Monitoring Relapse following Allogeneic Stem Cell Transplantation. Part I: Methods, acute leukemias, and myelodysplastic syndromes.

Authors:  Nicolaus Kröger; Ulrike Bacher; Peter Bader; Sebastian Böttcher; Michael J Borowitz; Peter Dreger; Issa Khouri; Homer A Macapinlac; Homer Macapintac; Eduardo Olavarria; Jerald Radich; Wendy Stock; Julie M Vose; Daniel Weisdorf; Andre Willasch; Sergio Giralt; Michael R Bishop; Alan S Wayne
Journal:  Biol Blood Marrow Transplant       Date:  2010-06-14       Impact factor: 5.742

5.  Transplantation in remission improves the disease-free survival of patients with advanced myelodysplastic syndromes treated with myeloablative T cell-depleted stem cell transplants from HLA-identical siblings.

Authors:  Hugo Castro-Malaspina; Ann A Jabubowski; Esperanza B Papadopoulos; Farid Boulad; James W Young; Nancy A Kernan; Miguel A Perales; Trudy N Small; Katharine Hsu; Michelle Chiu; Glenn Heller; Nancy H Collins; Suresh C Jhanwar; Marcel van den Brink; Stephen D Nimer; Richard J O'Reilly
Journal:  Biol Blood Marrow Transplant       Date:  2008-04       Impact factor: 5.742

6.  Analysis of gene expression in prostate cancer epithelial and interstitial stromal cells using laser capture microdissection.

Authors:  Jennifer L Gregg; Kathleen E Brown; Eric M Mintz; Helen Piontkivska; Gail C Fraizer
Journal:  BMC Cancer       Date:  2010-04-28       Impact factor: 4.430

7.  WT1 marker is not sufficient for distinguishing between melanoma and melanocytic nevi.

Authors:  Karli Rosner; Darius R Mehregan; Darius Moussai; Judith Abrams; Gerard Tromp; David A Mehregan
Journal:  J Cutan Pathol       Date:  2009-07-09       Impact factor: 1.587

8.  Overexpression of WT1 and PRAME predicts poor outcomes of patients with myelodysplastic syndromes with thrombocytopenia.

Authors:  Qiu-Sha Huang; Jing-Zhi Wang; Ya-Zhen Qin; Qiao-Zhu Zeng; Qian Jiang; Hao Jiang; Jin Lu; Hui-Xin Liu; Yi Liu; Jing-Bo Wang; Li Su; Hong-Yu Zhang; Zhen-Ling Li; Su-Jun Gao; Bo Huang; Yu-Ying Liu; Yan-Rong Liu; Lan-Ping Xu; Xiao-Jun Huang; Xiao-Hui Zhang
Journal:  Blood Adv       Date:  2019-11-12

9.  GATA1 Is a Sensitive and Specific Nuclear Marker for Erythroid and Megakaryocytic Lineages.

Authors:  Winston Y Lee; Olga K Weinberg; Geraldine S Pinkus
Journal:  Am J Clin Pathol       Date:  2017-04-01       Impact factor: 2.493

10.  The Wilms' tumor gene (WT1) regulates E-cadherin expression and migration of prostate cancer cells.

Authors:  Adina Brett; Sony Pandey; Gail Fraizer
Journal:  Mol Cancer       Date:  2013-01-08       Impact factor: 27.401

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.